dacarbazine has been researched along with Chromosome Deletion in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 12 (50.00) | 29.6817 |
| 2010's | 11 (45.83) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrunhosa-Branquinho, AN; Bar-Deroma, R; Baumert, BG; Clementel, E; Collette, S; Feuvret, L; Hurkmans, CW; Liu, Y; Van Beek, K; van den Bent, M; Weber, DC | 1 |
| Aiken, R | 1 |
| Chapet, S; Lévy, S; Mazeron, JJ | 1 |
| Ahluwalia, MS; Brewer, C; Chamberlain, MC; Dahiya, S; Elson, P; Fisher, PG; Hashemi-Sadraei, N; Newton, HB; Pannullo, S; Peereboom, DM; Prayson, R; Schiff, D; Wood, L; Xie, H | 1 |
| Chicoine, MR; Dacey, RG; DeWees, TA; Dowling, JL; Huang, J; Kim, AH; Leuthardt, EC; Linette, G; Rich, KM; Robinson, CG; Simpson, JR; Speirs, CK; Tran, DD; Zipfel, GJ | 1 |
| Fujiwara, H; Hirose, Y; Katayama, M; Kimura, T; Kitamura, Y; Ohira, T; Sasaki, H; Toda, M; Yazaki, T; Yoshida, K | 1 |
| Arita, H; Fukushima, S; Ichimura, K; Matsushita, Y; Miyakita, Y; Narita, Y; Ohno, M; Shibui, S; Takami, H; Yonezawa, M; Yoshida, A | 1 |
| Nagane, M | 1 |
| Berkey, B; Biggs, C; Blumenthal, DT; Brown, P; Giannini, C; Herman, J; Jenkins, R; Macdonald, D; Mehta, M; Peereboom, D; Schultz, C; Suh, JH; Vogelbaum, MA | 1 |
| Beumer, JH; Egorin, MJ; Park, DM; Shah, DD | 1 |
| DeAngelis, LM | 1 |
| Boogerd, W; Bromberg, JE; Dinjens, WN; Dubbink, HJ; Gijtenbeek, JM; Groenendijk, FH; Kouwenhoven, MC; Kros, JM; Postma, TJ; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Holt, B; van Heuvel, I; van Marion, R; Zonnenberg, BA; Zonnenberg, CB | 1 |
| Lou, X; Qiao, G; Wang, F | 1 |
| Bageritz, J; Barbus, S; Becker, N; Danner, A; Dittmann, LM; Felsberg, J; Goidts, V; Gronych, J; Grzendowski, M; Lichter, P; Reifenberger, G; Sabel, MC; Stühler, K; Tews, B; Toedt, G; Wolter, M | 1 |
| Hewer, E; Kappeler, A; Reinert, MM; Vajtai, I; Vassella, E | 1 |
| Branle, F; Camby, I; Geurts-Moespot, A; Jeuken, J; Kiss, R; Lefranc, F; Salmon, I; Sprenger, S; Sweep, F | 1 |
| Broët, P; Capelle, L; Carpentier, AF; Cornu, P; Crinière, E; Delattre, JY; Duffau, H; Hoang-Xuan, K; Kujas, M; Laigle, F; Lejeune, J; Marie, Y; Mokhtari, K; Polivka, M; Sanson, M; Simon, JM; Taillibert, S | 1 |
| Batchelor, TT; Cosgrove, GR; Louis, DN; Voloschin, AD | 1 |
| Beerenwinkel, N; Feiden, W; Hartmann, C; Ketter, R; Lengauer, T; Meese, E; Rahnenführer, J; Steudel, WI; Stockhammer, F; Strowitzki, M; Urbschat, S; von Deimling, A; Wemmert, S; Zang, KD | 1 |
| Bertorelle, R; Blatt, V; Bonaldi, L; Brandes, AA; Cavallo, G; Ermani, M; Franceschi, E; Gardiman, M; Ghimenton, C; Iuzzolino, P; Pession, A; Reni, M; Tosoni, A | 1 |
| Benouaich-Amiel, A; Capelle, L; Carpentier, A; Cornu, P; Delattre, JY; Diakite, F; Duffau, H; Hoang-Xuan, K; Idbaih, A; Iraqi, W; Kaloshi, G; Laigle-Donadey, F; Lejeune, J; Mokhtari, K; Omuro, A; Paris, S; Polivka, M; Renard, MA; Sanson, M; Simon, JM; Taillibert, S | 1 |
| Benouaich-Amiel, A; Delattre, JY; Ducray, F; Idbaih, A; Laigle-Donadey, F; Rousseau, A; Sanson, M | 1 |
| Chamberlain, MC; Glantz, MJ | 1 |
| Goldberg, SL; Klumpp, TR; Mangan, KF; Ming, PL; Mullaney, MT; Rao, PN; Redei, I | 1 |
2 review(s) available for dacarbazine and Chromosome Deletion
| Article | Year |
|---|---|
Molecular neuro-oncology and the challenge of the blood-brain barrier.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Chromosome Deletion; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Delivery Systems; Glioblastoma; Humans; Isocitrate Dehydrogenase; Molecular Targeted Therapy; Proto-Oncogene Proteins B-raf; Temozolomide; Tumor Suppressor Proteins | 2014 |
[Management of gliomas].
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Chromosome Deletion; Chromosomes, Human, Pair 1; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; Drug Resistance, Neoplasm; Glioma; Humans; Lomustine; Methylation; Multicenter Studies as Topic; Neoplasm Proteins; Neurosurgical Procedures; O(6)-Methylguanine-DNA Methyltransferase; Procarbazine; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Temozolomide; Treatment Outcome; Vincristine | 2014 |
5 trial(s) available for dacarbazine and Chromosome Deletion
| Article | Year |
|---|---|
Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Glioma; Humans; Prospective Studies; Quality Assurance, Health Care; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Temozolomide; Tomography, X-Ray Computed | 2018 |
Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Oligodendroglioma; Patient Outcome Assessment; Prognosis; Quality of Life; Survival Rate; Temozolomide; Young Adult | 2015 |
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose Fractionation, Radiation; Female; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Prognosis; Promoter Regions, Genetic; Survival Rate; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2009 |
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; DNA Methylation; DNA Repair; Female; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; Oligodendroglioma; Promoter Regions, Genetic; Temozolomide; Treatment Outcome | 2006 |
CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Chromosome Deletion; Chromosomes, Human, Pair 1; Dacarbazine; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Survival Analysis; Temozolomide | 2008 |
17 other study(ies) available for dacarbazine and Chromosome Deletion
| Article | Year |
|---|---|
Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Female; Gene Deletion; Genetic Predisposition to Disease; Glioma; Humans; Male; Middle Aged; Missouri; Prevalence; Radiotherapy Dosage; Retrospective Studies; Risk Factors; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2015 |
Upfront chemotherapy and subsequent resection for molecularly defined gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioma; Humans; Male; Middle Aged; Nitrosourea Compounds; Prospective Studies; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chromosome Deletion; Chromosomes, Human, Pair 1; Dacarbazine; DNA Methylation; Female; Glioblastoma; Guanine; Humans; Isocitrate Dehydrogenase; Japan; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Promoter Regions, Genetic; Temozolomide | 2016 |
[Current topics of treatment for glioma and mechanism of drug resistance].
Topics: Animals; Antineoplastic Agents, Alkylating; Chromosome Deletion; Dacarbazine; Drug Resistance, Neoplasm; Glioma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2008 |
Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 9; Combined Modality Therapy; Craniotomy; Dacarbazine; Gastric Bypass; Glioblastoma; Humans; Male; Middle Aged; Obesity, Morbid; Temozolomide | 2009 |
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression Regulation, Neoplastic; Glioma; Humans; Lomustine; Procarbazine; Promoter Regions, Genetic; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Temozolomide; Time Factors; Treatment Failure; Tumor Suppressor Proteins; Vincristine | 2009 |
First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; DNA Methylation; DNA, Neoplasm; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Neoplasm Staging; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Radiotherapy Dosage; Survival Rate; Temozolomide; Treatment Outcome; Trisomy; Tumor Suppressor Protein p53 | 2011 |
Spinal cord anaplastic oligodendroglioma with 1p deletion: report of a relapsing case treated with temozolomide.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Chromosome Deletion; Chromosomes, Human, Pair 1; Dacarbazine; Female; Humans; Oligodendroglioma; Spinal Cord Neoplasms; Temozolomide | 2011 |
Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitro.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 1; CpG Islands; Dacarbazine; DNA Methylation; Down-Regulation; Female; Gene Knockdown Techniques; Gene Silencing; Glioma; Humans; Isocitrate Dehydrogenase; Male; Middle Aged; Mutation; Oligodendroglia; Peroxiredoxins; Promoter Regions, Genetic; Radiation Tolerance; Temozolomide; Young Adult | 2012 |
Sarcomatous evolution of oligodendroglioma ("oligosarcoma"): confirmatory report of an uncommon pattern of malignant progression in oligodendroglial tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Combined Modality Therapy; Dacarbazine; Disease Progression; Gliosarcoma; Humans; Isocitrate Dehydrogenase; Male; Mutation; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Oligodendroglioma; Temozolomide | 2012 |
Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromosome Deletion; Chromosomes, Human, Pair 1; Combined Modality Therapy; Dacarbazine; DNA Fingerprinting; DNA, Neoplasm; Glioma; Glutathione Transferase; Humans; Immunohistochemistry; Intermediate Filament Proteins; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Neoplasms, Experimental; Nerve Tissue Proteins; Nestin; Nitrosourea Compounds; Nucleic Acid Hybridization; Organophosphorus Compounds; Rats; Rats, Sprague-Dawley; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vimentin; Xenograft Model Antitumor Assays | 2002 |
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Dacarbazine; Female; Humans; Loss of Heterozygosity; Magnetic Resonance Imaging; Male; Middle Aged; Oligodendroglioma; Temozolomide | 2004 |
Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: case study.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Combined Modality Therapy; Dacarbazine; Female; Humans; In Situ Hybridization, Fluorescence; Magnetic Resonance Imaging; Neoadjuvant Therapy; Temozolomide | 2005 |
Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 9; Cytogenetics; Dacarbazine; Female; Gene Deletion; Genetic Markers; Glioblastoma; Glioma; Humans; Loss of Heterozygosity; Male; Microsatellite Repeats; Middle Aged; Models, Genetic; Multivariate Analysis; Nucleic Acid Hybridization; Paraffin; Prognosis; Proportional Hazards Models; Sex Factors; Temozolomide; Time Factors; Treatment Outcome | 2005 |
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dacarbazine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genetic Testing; Genotype; Glioma; Humans; Loss of Heterozygosity; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome | 2007 |
Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, X; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Temozolomide; Tomography, X-Ray Computed; Tumor Suppressor Proteins | 2008 |
Detection of a dormant 20q- leukemia clone in bone marrow cultures with hematopoietic growth factors: implications for secondary leukemia post-transplant.
Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Bone Marrow Transplantation; Chromosome Deletion; Chromosomes, Human, Pair 20; Clone Cells; Combined Modality Therapy; Cytarabine; Dacarbazine; Doxorubicin; Female; Hematopoietic Cell Growth Factors; Hodgkin Disease; Humans; Mechlorethamine; Neoplasm, Residual; Neoplasms, Second Primary; Neoplastic Stem Cells; Prednisone; Procarbazine; Radiotherapy; Recurrence; Transplantation, Autologous; Vinblastine; Vincristine | 1997 |